Flag of the European Union EU Clinical Trials Register Help

Clinical trials for S Phase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17,732 result(s) found for: S Phase. Displaying page 1 of 887.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-004259-36 Sponsor Protocol Number: DASAPOST Start Date*: 2013-01-23
    Sponsor Name:Fundación PETHEMA
    Full Title: Multicenter, open-label, non-randomized Phase II trial of dasatinib in patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML) who meet criteria for late suboptimal response after prior im...
    Medical condition: Chronic Myeloid Leukemia in Chronic Phase
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004106-13 Sponsor Protocol Number: NORDCML006 Start Date*: 2009-03-23
    Sponsor Name:University of Trondheim, NTNU, Norway
    Full Title: An Open-Label, Randomized, Multicenter Phase II Trial Comparing the Depletion of Malignant Stem Cells with Dasatinib vs. Imatinib in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leuk...
    Medical condition: Chronic myeloid leukemia (CML) in chronic phase (CP) at diagnosis (untreated)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003839-41 Sponsor Protocol Number: HOVON 78 CML Start Date*: 2007-07-19
    Sponsor Name:HOVON Foundation
    Full Title: Imatinib in combination with Cytarabine as compared to Imatinib alone in patients with first chronic phase Chronic Myeloid Leukemia. A prospective randomized phase III study.
    Medical condition: Patients with first chronic phase Chronic Myeloid Leukemia.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052065 Chronic phase chronic myeloid leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000637-37 Sponsor Protocol Number: 501 Start Date*: 2011-04-13
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE
    Full Title: “AN OBSERVATIONAL STUDY ON THE MOLECULES INVOLVED IN THE INTRACELLULAR UPTAKE IN PATIENTS AFFECTED FROM CHRONIC MYELOID LEUKEMIA RECEIVING TIROSINE-KINASE INHIBITORS.”
    Medical condition: Chronic myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052065 Chronic phase chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001382-33 Sponsor Protocol Number: CSTI5710110E2 Start Date*: 2005-04-15
    Sponsor Name:NOVARTIS FARMA
    Full Title: An extension to a phase II study to determine the efficacy and the safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha
    Medical condition: treatment of patients with CML who are refractory to or intolerant of interferon alpha.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10052065 Chronic phase chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001417-26 Sponsor Protocol Number: STW/K/01707 Start Date*: 2009-01-22
    Sponsor Name:Steigerwald Arzneimittelwerk GmbH
    Full Title: Double blind, randomized, placebo-controlled, mulitcentric clinical trial to evaluate the relapse prevention of a hypericum extract in outdoor patients with moderate depressive episodes (major depr...
    Medical condition: Moderate depressive episodes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002898-21 Sponsor Protocol Number: CAMN107AIT15 Start Date*: 2018-11-14
    Sponsor Name:NOVARTIS FARMA S.P.A.
    Full Title: A phase II, single-arm, multicenter study of full treatment-free remission in patients with chronic myeloid leukemia in chronic phase treated with nilotinib in first-line therapy who have achieved ...
    Medical condition: Patients with chronic myeloid leukemia in chronic phase treated with nilotinib in first-line therapy who have achieved a sustained, deep molecular response for at least 1 year.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006181-41 Sponsor Protocol Number: CA180399 Start Date*: 2013-01-03
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An open label, randomized (2:1) Phase 2b study of Dasatinib vs. Imatinib in patients with Chronic Phase Chronic Myeloid Leukemia who have not achieved an optimal response to 3 months of therapy wi...
    Medical condition: Chronic Phase Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) BE (Completed) IT (Completed) AT (Completed) PL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-001815-21 Sponsor Protocol Number: 212340 Start Date*: 2019-10-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIB, open label, long term follow-up study to assess persistence of immune responses to GSK’s HZ/su vaccine 4-7 years after primary vaccination; and immunogenicity and safety assessment of...
    Medical condition: Herpes Zoster
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000618-30 Sponsor Protocol Number: 11272 Start Date*: 2018-10-05
    Sponsor Name:GWT-TUD GmbH
    Full Title: Phase 2 Clinical Trial with Ponatinib as a Second Line Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to prior First Line Tyrosine Kinase Inhibitor Trea...
    Medical condition: Adult patients (age ≥ 18) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) who have proven to be resistant or intolerant to prior first line Tyrosine Kinase Inhibitor Treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002787-25 Sponsor Protocol Number: GIMEMACML0811 Start Date*: 2011-09-21
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: The protein tyrosine kinase inhibitor nilotinib as first-line treatment of Ph+, BCR-ABL+ chronic myeloid leukemia (CML) in early chronic phase: a phase IIIb, multicenter study of complete molecular...
    Medical condition: Ph+, BCR-ABL+ chronic myeloid leukemia (CML) in early chronic phase
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004974-82 Sponsor Protocol Number: 2013.837 Start Date*: 2014-04-04
    Sponsor Name:Hospices Civils de Lyon
    Full Title: PETALS study : PEgylated interferon-alpha2a and TAsigna® for first Line therapy of Philadelphia chromosome-positive chronic phase CML patientS
    Medical condition: Chronic phase chronic myeloid leukaemia with Philadelphia chromosome positive or BCR-ABL positive
    Disease: Version SOC Term Classification Code Term Level
    19.1 10022891 - Investigations 10034877 Philadelphia chromosome positive PT
    19.1 100000004864 10052065 Chronic phase chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006180-21 Sponsor Protocol Number: CA180-400 Start Date*: 2013-02-19
    Sponsor Name:BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
    Full Title: A PHASE IV, OPEN-LABEL, MULTICENTER STUDY OF DASATINIB IN CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS WITH CHRONIC LOW-GRADE NONHEMATOLOGIC TOXICITY TO IMATINIB
    Medical condition: CP-CML patients with non hematologic low toxicity grade to imatinib
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005062-34 Sponsor Protocol Number: PhilosoPhi34 Start Date*: 2013-04-02
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)
    Full Title: An open label, single arm, phase II study of nilotinib 300 mg BID in newly diagnosed CP-CML patients, in order to verify disappearance of CD34+/lin-Ph+ cells from bone marrow during treatment.
    Medical condition: newly diagnosed CP-CML patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10052065 Chronic phase chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003126-40 Sponsor Protocol Number: alloCML Start Date*: 2015-03-05
    Sponsor Name:UNIVERSITà DEGLI STUDI MILANO BICOCCA
    Full Title: Allogeneic haematopoietic stem cell transplantation from a matched donor in patients with chronic myeloid leukemia failing to gain normal hemopoiesis under TKIs therapy
    Medical condition: Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004699-16 Sponsor Protocol Number: KRT-232-117 Start Date*: 2021-03-15
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukem...
    Medical condition: Phase 1b and Phase 2 Arms A and B: Adults with tumor protein 53 wild type (TP53wt) Philadelphia chromosome positive (Ph+) CML in chronic phase who are refractory or intolerant to ≥ 2 prior TKIs and...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10009015 Chronic myeloid leukemia LLT
    21.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    22.0 100000004864 10082178 Philadelphia positive chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003186-18 Sponsor Protocol Number: CAMN107A2408 Start Date*: 2013-02-19
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A phase II, single arm, open label study of treatment-free remission after achieving sustained MR4.5 on nilotinib
    Medical condition: Ph+ chronic myeloid leukemia (CML)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Ongoing) BE (Ongoing) GR (Completed) GB (GB - no longer in EU/EEA) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000083-10 Sponsor Protocol Number: CA180-363 Start Date*: 2011-08-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib plus Smoothen Antagonist (BMS-833923) in the Treatment of Subjects with Newly Diagnosed Chronic Phase Phil...
    Medical condition: newly diagnosed Ph+ CP CML
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054352 Chronic phase chronic myeloid leukemia LLT
    14.0 10022891 - Investigations 10034877 Philadelphia chromosome positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) FI (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002749-37 Sponsor Protocol Number: ISAV Start Date*: 2011-10-11
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA
    Full Title: Validation of digital-PCR analysis through programmed imatinib interruption in PCR negative chronic myeloid leukemia patients.
    Medical condition: Chronic Myeloid Leukemia (CML) with substained Complete Molecular Response (CMR).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052065 Chronic phase chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) DE (Completed) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001174-18 Sponsor Protocol Number: CLO21800205 Start Date*: 2015-05-18
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase I/II Dose-Escalation Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemias
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:44:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA